Polymyxin
Polymyxins are a group of polypeptide antibiotics used to treat serious infections caused by susceptible Gram-negative bacteria, including certain multidrug-resistant strains of Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. They act by binding to bacterial lipopolysaccharides and disrupting the outer cell membrane, leading to leakage of cellular contents and bacterial death. Clinically used agents include polymyxin B and colistimethate sodium (a prodrug of colistin), available in intravenous and selected inhaled or topical formulations depending on the product. Common adverse effects include kidney toxicity, tingling or dizziness, and, less commonly, neuromuscular weakness. Serious risks include neurotoxicity and respiratory muscle impairment, particularly with excessive exposure or impaired kidney function. Their use is generally reserved for infections with limited treatment options and requires specialist supervision, susceptibility-guided selection, and careful monitoring of renal and neurological function.
Polymyxin was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Polymyxin, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Polymyxin from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Polymyxin, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
